The Glucagon Like Peptide 2 Receptor pipeline drugs market research report outlays comprehensive information on the Glucagon Like Peptide 2 Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Glucagon Like Peptide 2 Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Gastrointestinal, Immunology, Metabolic Disorders, and Other Diseases which include the indications Short Bowel Syndrome, Crohn’s Disease (Regional Enteritis), Graft Versus Host Disease (GVHD), Inflammation, Obesity, Unspecified Metabolic Disorders, and Multiple Organ Failure (Multiple Organ Dysfunction Syndrome). It also reviews key players involved in Glucagon Like Peptide 2 Receptor targeted therapeutics development with respective active and dormant or discontinued products.

The Glucagon Like Peptide 2 Receptor pipeline targets constitutes close to 18 molecules. Out of which, approximately 16 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 2, 2, 2, 6, and 1 respectively. Similarly, the universities portfolio in Phase I, and Discovery comprises 1, and 1 molecule.

Glucagon Like Peptide 2 Receptor overview

Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.

For a complete picture of Glucagon Like Peptide 2 Receptor’s drug pipeline, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.